Resolve Therapeutics has successfully completed a dose escalation study of its candidate drug RSLV-132 targeting systemic lupus erythematosus (SLE). RSLV-132 works by breaking down the RNA found in immune complexes. Increasing evidence shows the importance of RNA bound to autoantibody immune complexes to activate the inflammatory pathway regulated by interferon. The drug…
A recent study found it is possible to distinguish systemic lupus erythematosus (SLE) patients from those with primary fibromyalgia (FM), with complete specificity, using a new test measuring the levels of abundant proteins in circulation. The study, “Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound…
XTL Biopharmaceuticals Ltd. announced it accepted an invitation to join Lupus Foundation of America (LFA)’s Corporate Advisory Council (CAC). XTL is a clinical-stage biotech dedicated to developing pharmaceutical products to treat autoimmune diseases such as lupus. The biotech’s lead drug candidate, hCDR1, is a top-quality clinical asset for the…
Aurinia Pharmaceuticals has completed the initial analysis of voclosporin in its AURION trial, an open label, single arm, exploratory trial examining patients with active lupus nephritis (LN) taking voclosporin 23.7 mg. twice daily in combination with standard of care, mycophenolate mofetil, and corticosteroids. The study is assessing biomarkers of disease…
Research conducted on medical records from over a quarter million adult patients found that African-Americans with connective tissue diseases were twice as likely to suffer complications that increase the risk of a heart attack, stroke, or death. The study, “The Prevalence of Atherosclerosis in Those with…
Lupus patients are more likely to have high levels of prothrombotic antibodies that interact with cell membrane phospholipids (PLs), which are thought to be a possible cause of maternal morbidity. Now, researchers have identified a specific antiphospholipid antibody (aPL) that appears to predict the likelihood of pregnancy complications. The study, “Lupus anticoagulant is…
Researchers investigating how diet affects disease activity in systemic lupus erythematosus (SLE) patients, determined via glucocorticoid (GC) treatment, found that dietary vitamin D does not protect against lupus activity while beta-carotene, fatty acid C18:2, and vitamin B6 might have a protective role. Alcohol was also negatively associated with GC treatment, indicating that moderate…
A recently released study in the journal Rheumatology titled “Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012,” shows higher mortality rates among people with systemic lupus erythematosus (SLE) compared to those without the disease. The study, led by senior researcher Dr. Weiya Zhang, M.D.,…
Lupus during pregnancy increases the likelihood of health complications for women and their babies, according to a study, “What to expect when expecting with SLE: A population-based study of maternal and fetal outcomes in SLE and pre-SLE,” published in the journal Arthritis Care and Research. Adverse pregnancy outcomes…
In a review titled “Immunoregulation of NKT Cells in Systemic Lupus Erythematosus,” published in the Journal of Immunology Research, researchers summarized the role of a specific class of immune cells – natural killer T (NKT) cells – highlighting their potential as a new therapeutic target for systemic lupus erythematosus (SLE).